The Jiménez Díaz Foundation improves treatments

he Jiménez Díaz Foundation University Hospital Incorporate biomarkers into their treatments Optimizing bladder cancer diagnosis and patient follow-up.It is a non-invasive tools Based on PCR analysis, based on urine DNA, a panel of 15 markers can be studied to detect genetic changes specific to that individual Bladder tumorsranking ninth in the world in terms of number of confirmed cases.

“The use of this biomarker is an important advance in the diagnosis and monitoring of patients with bladder cancer, helping Reduce unnecessary intervention urinary tract and has a significant positive impact on the quality of life of those affected. ” Jimenez Díaz Urology Services and be responsible for your Urology Oncology, Ramiro Cabello, which highlights the convenience the test offers patients, as it only requires a urine sample. “Unlike other traditional tests such as cytology and other biomarkers, No side effects from infusion

such as inflammation, infection and hemagglutinins,” he noted.

acquisition Bladder superficial examination test This is the result of coordinated work between various service departments Urology and pathological anatomy Jiménez Díaz Hospital is a pioneer in incorporating this therapeutic tool into its hospitals Urothelial Cancer Department.The Jimenez Díaz Foundation reports that soon, the technology will also be used in three other hospitals Chiron Health In addition to the foundation, it is also included in madrid health services (Sermas), the University Hospital king juan carlos (mostoles), Princess Elena (Valdemoro) and general villalba (Corrado Villalba).

How is bladder cancer diagnosed and treated?

Bladder cancer is usually found in People around 70 years old.The main risk factors are habitual smoking,as well as Presence of blood in urine -Hematuria-, its most common associated symptom. They are more common in Western Europe, including Spain, and North America than in Asia and Eastern Europe, where fewer cases have been detected. Most are diagnosed early of development, which facilitates cure by surgery, particularly transurethral resection, followed by regular instillation of intravesical chemotherapy or immunotherapy.

When the tumor is discovered at an advanced stage, the cure method “may be difficult or even impossibletreatment goals shift toward prolonging survival and improving the patient’s quality of life,” explains Cabello. Treatment requires invasive tests, e.g. Cystoscopy

and repeated surgical procedures, e.g. transurethral cystectomy“This has significant implications for patients” as they require ongoing monitoring based on their risk of recurrence and tumor progression, “which cause discomfort” and also requires specific time, people, and organization.

More precise alternative treatments

New biomarker from Jiménez Díaz Foundation University Hospital reduces the impact of such treatments because it 80% sensitivity and his 48% specificityif the test results are negative, the accuracy of ruling out the presence of a tumor is close to 98%.

Cabello said this precision “helps decision-making and, in certain patients and circumstances, may allow Reduce the frequency and/or need for cystoscopy without ignoring the presence of invasive tumors. ”